Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer

Beijing Cancer Hospital, Beijing

Beijing Chest Hospital, Capital Medical University, Beijing

Peking University First Hospital, Beijing

The First Hospital of Jilin University, Changchun

Xiangya Hospital Central South University, Changsha

Sichuan Cancer Hospital, Chengdu

Chongqing University Cancer Hospital, Chongqing

The Second Hospital of Dalian University, Dalian

Fujian Medical University Union Hospital, Fuzhou

Fuzhou Tuberculosis Prevention and Control Hospital of Fujian Province (Fuzhou Pulmonary Hospital of Fujian), Fuzhou

Guangdong Provincial People's Hospital, Guangzhou

Sun Yat-sen University Cancer Center, Guangzhou

Hainan General Hospital, Haikou

First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Zhejiang University School of Medicine, Sir Run Run Shaw Hospital, Hangzhou

Harbin Medical University Cancer Hospital, Harbin

Shandong Cancer Hospital, Jinan

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou

Linyi Cancer Hospital, Linyi

The First Affiliated Hospital of Nanchang University, Nanchang

Guangxi Medical University Affiliated Tumor Hospital, Nanning

Liaoning Cancer Hospital & Institute, Shenyang

The First Hospital of China Medical University, Shenyang

Peking University Shenzhen Hospital, Shenzhen

The Fourth Hospital of Hebei Medical University, Shijiazhuang

Shanxi Provincial Cancer Hospital, Taiyuan

Tianjin Cancer Hospital Airport Hospital, Tianjin

Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Union Hospital Tongji medical college Huazhong University of Science and Technology, Wuhan

The Northern Jiangsu People's Hospital, Yangzhou

Yantai Yuhuangding Hospital, Yantai

Henan Cancer Hospital, Zhengzhou

Taipei Veterans General Hospital, Taipei